FDA names Namandjé Bumpus as principal deputy commissioner

29 Nov 2023
firstwordpharma.com
Executive Change
FDA chief scientist Namandjé Bumpus has been named as the successor to outgoing principal deputy commissioner Janet Woodcock. In a social media post on Wednesday, Commissioner Robert Califf called Bumpus a "powerhouse scientist and leader" who will "continue to advance the agency's critical public health initiatives using cutting-edge regulatory science as a North Star."
The appointment comes about two weeks after the agency confirmed that Woodcock, a 35-year veteran at the regulator, would be retiring early next year. "There are many analogous situations that point out how hard it is to step into a role held by a legendary leader, but I am confident [Bumpus] is up for it," Califf said.
The FDA's Office of the Chief Scientist, to which Bumpus was appointed in mid-2022, supports the research foundation, science, and innovation that underpins the agency's regulatory mission. According to the agency's website, it does this through a framework that encompasses scientific collaborations, laboratory safety, the transfer of FDA inventions to the private sector, scientific integrity in FDA policy- and decision-making, and its core research component – the FDA's National Center for Toxicological Research, which generates data that the FDA requires for its regulatory decision-making.
Earlier this year, Bumpus played a key role in removing Covis Pharma's preterm birth drug Makena (hydroxyprogesterone caproate) from the market because of risks to patients. Before joining the FDA, Bumpus was a professor and chair of the department of pharmacology and molecular sciences at the Johns Hopkins University School of Medicine.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.